Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Arch. argent. pediatr ; 119(4): e349-e352, agosto 2021. ilus
Article in Spanish | LILACS, BINACIS | ID: biblio-1281786

ABSTRACT

El rabdomiosarcoma es el tumor maligno de partes blandas más frecuente en la edad pediátrica. Puede afectar cualquier localización anatómica. El subtipo histológico alveolar suele causar lesiones en las extremidades en niños de mayor edad. Los sitios metástasicos más frecuentes son el pulmón, la médula ósea, el hueso y los ganglios linfáticos. Describimos el caso de un paciente con rabdomiosarcoma alveolar (RA) con metástasis cardíaca, una presentación poco frecuente de la patología.


Rhabdomyosarcoma is the most common malignant soft tissue tumor in pediatric age. It can affect any anatomical location. Alveolar histological subtype usually presents lesions on the extremities in older children. The most common metastatic sites are the lung, bone marrow, bone and lymph node. We describe a case of alveolar rhabdomyosarcoma with cardiac metastasis in a pediatric patient, a rare presentation of the pathology.


Subject(s)
Humans , Male , Child , Soft Tissue Neoplasms/pathology , Rhabdomyosarcoma, Alveolar/pathology , Foot Diseases/pathology , Heart Neoplasms/secondary , Rhabdomyosarcoma, Alveolar/diagnosis , Rhabdomyosarcoma, Alveolar/therapy , Ventricular Septum , Foot Diseases/diagnosis , Foot Diseases/drug therapy , Heart Neoplasms/diagnosis , Heart Neoplasms/drug therapy , Neoplasm Staging
2.
Arq. neuropsiquiatr ; 72(1): 28-32, 01/2014. tab, graf
Article in English | LILACS | ID: lil-697593

ABSTRACT

The objective of this study was to evaluate the effects of botulinum toxin type A (BTX-A) on spastic foot in stroke patients in a rehabilitation program. Method: Hemiparetic stroke patients (n=21) enrolled in a rehabilitation program were divided into two groups. The first group (n=11) received a total of 300UI BTX-A, and the second group (n=10) received 100 UI BTX-A. All patients were assessed at baseline and 2, 4, 8 and 12 weeks after injection for Modified Ashworth Score, time walking 10 meters, and the Functional Independence Measure (mFIM) motor score. Results: The higher-dose group exhibited a significant improvement in spasticity, and both groups showed an improvement in time walking 10 meters and mFIM, with no significant differences between them. Conclusions: Our findings suggest that gains in gait velocity and functional independence were not correlated to BTX-A dose. .


O objetivo deste estudo foi avaliar os efeitos da toxina botulínica tipo A (TXB-A) sobre a espasticidade de membro inferior em pacientes pós-AVE em reabilitação. Método: 21 pacientes hemiparéticos foram divididos em dois grupos que receberam doses de TXB-A de 300UI (Grupo 1) e 100UI (Grupo 2) e foram avaliados antes da injeção e 2, 4, 8 e 12 semanas após, quanto à escala de Ashworth modificada, tempo para andar 10 metros e escore motor da Medida de Independência Funcional (MIFm). Resultados: O grupo que utilizou dose mais alta teve melhora significativa da espasticidade. Ambos os grupos tiveram melhora do tempo para andar 10 metros e da MIFm sem diferença significativa entre eles. Conclusões: A melhora da velocidade de marcha e da independência funcional não foram correlacionadas com a dose de TXB-A na amostra analisada. .


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Botulinum Toxins, Type A/therapeutic use , Foot Diseases/drug therapy , Neuromuscular Agents/therapeutic use , Stroke/rehabilitation , Activities of Daily Living , Foot Diseases/etiology , Gait/drug effects , Motor Activity/drug effects , Muscle Spasticity/drug therapy , Muscle Spasticity/etiology , Muscle Spasticity/physiopathology , Statistics, Nonparametric , Stroke/complications , Time Factors , Treatment Outcome , Walking/physiology
3.
Rev. bras. ciênc. vet ; 9(1): 17-20, jan.-abr. 2002. tab
Article in Portuguese | LILACS | ID: lil-322493

ABSTRACT

O propósito deste estudo foi avaliar aspectos físico-químicos e microbiológicos do sulfato de cobre a 5 por cento e cloridrato de polihexametileno biguanida (P.H.M.B.) a 1 por cento como soluçöes desinfetantes em pedilúvio para tratamento de diversas afecçöes podais em bovinos associado a procedimentos cirúrgicos e à antibioticoterapia parenteral. As análises físico-químicas constaram da determinaçäo do pH e da concentraçäo do cobre e cloridrato de polihexametileno biguanida (P.H.M.B.). As análises microbiológicas realizadas foram a contagem de microorganismos aeróbios ou facultativos mesófilos e anaeróbios mesófilos. Os resultados obtidos permitem afirmar que as características físico-químicas das duas soluçöes mantiveram-se praticamente constantes e que a soluçäo de PHMB a 1 por cento apresentou menores contagens de microorganismos aeróbios ou facultativos mesófilos e anaeróbios mesófilos do que a soluçäo de sulfato de cobre a 5 por cento.


Subject(s)
Animals , Cattle , Anti-Infective Agents, Local , Biguanides , Copper Sulfate , Foot Diseases/microbiology , Foot Diseases/drug therapy , Foot Diseases/veterinary
4.
Rev. méd. Chile ; 118(8): 881-8, ago. 1990. tab
Article in Spanish | LILACS | ID: lil-96557

ABSTRACT

Diabetic angiopathy prevents adequate access of antibiotic agents to septic areas of the diabetic foot. We treated 22 such patients with antibiotics infused through a superficial vein associated to tourniquette occlusion of the limb (Group A). a control group of 47 patients, similar in age, sex and severity of diabetes received conventional systemic therapy (Group B). 45% of the patients exhibited occlusive arterial disease. Surgery was performed by the same team in both groups. Group A received regional anesthesia at the same time of the first antibiotic infusion. Group B received general or spinal anesthesia. Amputation was required in 5% of patients in Group A compared to 30% of patients in Group B (p < 0,02). Hospital stay was also significantly shorter in patients from Group A. No complications of this form of therapy were obseved. Thus, regional antibiotic therapy may improve prognosis and facilitate management in patients with septic diabetic foot


Subject(s)
Adult , Middle Aged , Humans , Male , Female , Anti-Bacterial Agents/administration & dosage , Bacterial Infections/drug therapy , Diabetes Mellitus/drug therapy , Foot Diseases/drug therapy , Diabetic Angiopathies/complications , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/classification , Diabetes Mellitus/complications , Foot Diseases/etiology , Infusions, Intravenous/methods , Infusions, Parenteral/methods , Diabetic Neuropathies/complications , Prospective Studies
6.
Bol. Asoc. Méd. P. R ; 77(5): 191-4, mayo 1985. tab
Article in English | LILACS | ID: lil-32276

ABSTRACT

La eficacia y seguridad de aztreonam fue evaluada en 23 pacientes con infecciones agudas de tejido blando que incluían celulitis, úlceras, abscesos e infecciones de herida. Los pacientes recibieron las siguientes dosis endovenosas de aztreonam: 16 pacientes recibieron 1gm cada 8 horas, 5 pacientes recibieron 1gms cada 8 horas y 2 pacientes recibieron 0.5gm cada 8 horas. Una segunda droga fue administrada concomitantemente con aztreonam por vía endovenosa en la siguiente forma: 20 pacientes recibieron nafcilina 2gms cada 4 horas y 3 pacientes recibieron clindamicina 0.6gm cada 6 horas. La mayoría de los pacientes estaban seriamente enfermos con condiciones subyacentes como diabetes mellitus de un promedio de duración de 14 años (límites entre 2 y 40 años) en 19 de 23 pacientes (82%). Escherichia coli fue el organismo aislado más frecuentemente. La respuesta clínica demostró cura en 23/23 pacientes tratados. La respuesta bacteriológica demostró cura en 20/23 pacientes. Hubo 3 fallas bacteriológicas: la primera fue una superinfección con Pseudomonas maltophilia la segunda fue una pulmonía adquirida en el hospital y la tercera fue una superinfección con flora mixta (Enterococo, Staphylococcus aureus y Enterobacter aerogenes). No se documentaron efectos adversos serios. Aztreonam resultó ser un agente efectivo, seguro y valioso en el tratamiento de infecciones agudas de tejido blando causadas por bacilos aeróbicos gram-negativos susceptibles


Subject(s)
Humans , Clindamycin/therapeutic use , Diabetes Mellitus/complications , Foot Diseases/drug therapy , Bacterial Infections/drug therapy , Lactams/therapeutic use , Nafcillin/therapeutic use , Drug Therapy, Combination , Gram-Negative Aerobic Bacteria
SELECTION OF CITATIONS
SEARCH DETAIL